Long-term safety of fixed-dose combinations: Azilsartan medoxomil/ chlorthalidone (AZL-M/CLD) vs olmesartan medoxomil/ hydrochlorothiazide (OLM/HCTZ) in hypertensive subjects with stage 3 chronic kidney disease

Authors
Category Primary study
JournalJournal of the American Society of Hypertension
Year 2014
This article has no abstract
Epistemonikos ID: 25dc21436c21b2e6f3a4eb76f86043ad2d4967fa
First added on: Feb 06, 2025